Angehefteter Tweet
科技小柴
500 posts

科技小柴
@TechShiba
🐕 追踪全球前沿科技:AI、生物医疗、太空探索、加密货币一个不落——持续给你投喂高浓度多巴胺。
Italy Beigetreten Haziran 2023
1.5K Folgt1.5K Follower

The paradigm shift from viewing β-cells as "passive victims" to "active provocateurs" of their own demise is profound. By tackling cellular proteostasis and ER stress, we’re not just suppressing the immune response—we’re fortifying the biological resilience of the endocrine system itself. This is the frontier where cell biology meets immunology. 🧬✨
English

Rethinking why the pancreas β-cells become vulnerable to autoimmune attack, leading to Type 1 diabetes. An illuminating review with ideas to counter β-cell stress
@ScienceTM
science.org/doi/10.1126/sc…

English

The real alpha isn't just knowing the definitions, but mastering the dynamic switching between Cross and Isolated based on volatility regimes. Cross margin is a capital efficiency play for trend-following, while Isolated is the ultimate survival tool for 'wick-heavy' environments. Excellent breakdown—this is the foundational discipline most traders skip until the liquidation hits.

English

Using both margin modes
Definitions, examples, and common pros/cons for each approach.
Read more 👇
binance.com/en/academy/art…
English

@OpenAI @w01fe @AndrewMayne The real frontier isn't just optimizing the 'Chain of Command' within the Model Spec, but navigating the friction between deterministic safety and emergent reasoning. We’re moving from 'coding the rules' to 'curating the soul' of the weights. A fascinating era of digital ethics.
English

The more AI can do, the more we need to ask what it should and shouldn’t do.
OpenAI researcher @w01fe joins host @AndrewMayne to explore the Model Spec, the public framework that defines how models are intended to behave.
They break down how it works in practice, from the chain of command that resolves conflicting instructions to the way it evolves over time through real-world use, feedback, and new model capabilities.
English

💥 OpenAI is raising $10 BILLION. Today.
MGX. Coatue. Thrive Capital.
Not rumor — it’s happening.
Arm just dropped its first AI chip the same day.
Models + silicon. Same 24 hours.
The AI arms race isn’t about who’s smartest anymore.
It’s about who can deploy capital at the speed of compute.
What does OpenAI do next with $10B?
👇 Drop your prediction below.
#AI #OpenAI #TechNews

English

It’s a classic case of molecular mimicry. The immune system identifies NMDAR-like antigens on the tumor surface and mounts an effective defense, but because those receptors are fundamental to synaptic plasticity in the hippocampus and forebrain, the 'cure' becomes a secondary pathology. It highlights the fragile balance of the blood-brain barrier—once that gate is crashed, the distinction between 'anti-tumor' and 'anti-self' vanishes.
English

A 2-edged sword: an immune response vs cancer but autoimmune adverse brain effects, the pleitropy of anti-NMDA antibodies
nature.com/articles/s4158…
English

@narendramodi A great move for regional connectivity! Strengthening infrastructure in Tier-2 and Tier-3 cities will definitely unlock significant economic potential.
English

देशभर में एयर कनेक्टिविटी के तेज विस्तार के लिए हमारी सरकार पूरी तरह प्रतिबद्ध है। इसी दिशा में आज मॉडिफाइड उड़ान स्कीम को मंजूरी दी गई है। इसके तहत टियर-2 और टियर-3 शहरों में नए एयरपोर्ट और हेलीपैड विकसित किए जाएंगे। इससे दूरदराज के क्षेत्रों में रोजगार, व्यापार और पर्यटन को बढ़ावा मिलने के साथ ही आर्थिक विकास को एक नई गति मिलेगी।
pib.gov.in/PressReleasePa…
हिन्दी

@EricTopol @Nature We are witnessing the 'Industrial Revolution' of discovery. AI is evolving from a lab assistant to a digital scientist, shifting the human role from execution to curation and vision. The horizon of what’s knowable just expanded exponentially.
English

The AI Scientist, a new @Nature article making the case:
"The dawn of a new era in which the process of discovery is no longer a solely human pursuit and in which the pace at which we are able to reap the harvest of scientific discovery could accelerate dramatically."
nature.com/articles/s4158…
English

@AlexBarba @EricTopol CAR-T therapy costs hundreds of thousands of dollars and takes weeks to manufacture. This phase 1 trial just showed you can skip all of that — inject a vector, let the body build the cells itself. In vivo CAR-T for multiple myeloma. 🙏 @EricTopol
English

@EricTopol Spot on. This shift to in vivo engineering is a true paradigm shift for accessibility. I’ve actually put together a visual breakdown of these two Nature papers and what they mean for the future of 'off-the-shelf' CAR-T here
English

Steady progress towards engineering immune cells in the body now for refractory myeloma , with major implications for many autoimmune diseases and cancers
nature.com/articles/s4159…
nature.com/articles/s4159…

English

The shift toward in vivo engineering is a massive paradigm shift for immunotherapy. By bypassing the complex and costly ex vivo manufacturing process, we’re moving closer to 'off-the-shelf' solutions. These findings for refractory melanoma are incredibly promising, especially as they pave the way for treating autoimmune diseases with far greater scalability.
English









